Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
NCT00456508
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
147
Enrollment
INDUSTRY
Sponsor class
Conditions
Hereditary Angioedema (HAE)
Interventions
DRUG:
ecallantide
Sponsor
Shire